Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions

Abstract Background The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth. The advent of CFTR modulator therapies...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Hiba J. Mustafa, Yair J. Blumenfeld, Ramen H. Chmait, Jennifer L. Taylor‐Cousar, Jordana E. Hoppe, Stacey L. Martiniano, Angela Metcalf, Scott D. Sagel, Edith T. Zemanick, Alireza A. Shamshirsaz, Sylvia E. Szentpetery, Aaron T. Trimble, Elizabeth B. Burgener, Carmen Luna‐Paredes, Isabelle Sermet‐Gaudelus, Michael V. Zaretsky
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2026-07-01
Σειρά:	Pregnancy
Θέματα:	CFTR cystic fibrosis ETI fetal therapy meconium ileus modulator therapy
Διαθέσιμο Online:	https://doi.org/10.1002/pmf2.70317
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!